Lupin's business of active pharmaceutical ingredients (API) is based on cost, quality and capacity leadership.

Our major therapeutic focus areas: anti TB, cepholosporins (both orals and injectables), ace inhibitors, statins and prils. In each of these segments we are among the world's dominant players.

We are in the process of establishing ourselves as a major global force in NSAID, cardiovascular drugs and nutritional supplements. 

Our manufacturing is integrated: apart from API (Pharmaceutical products), we also make and market API advance penultimates.